

ASX Announcement

26 November 2025

BCAL receives ~\$2.5 million R&D tax rebate

BCAL Diagnostics Limited (ASX: BDX) (BCAL or Company), a healthcare company engaged in early cancer detection, has received ~\$2.5 million from the Australian Taxation Office as part of the Australian Government Research & Development Tax Incentive.

BCAL's breast cancer research and development is solving clinical gaps in the market with early detection tests designed for global applicability. In March 2025, BCAL commenced phase one of the commercial launch of its first product *BREASTEST plus™*. BCAL recently announced a product enhancement expanding clinical coverage to approximately 50% of eligible breast screening women, those with either Breast D or C density.

BCAL CEO, Shane Ryan, said: *"BCAL appreciates the ongoing support of the R&D tax incentive program in assisting BCAL in funding the development of the BREASTEST plus™ suite of products and a range of early cancer detection tests in its drive to make a significant contribution to women's health".*

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

For further information:

Corporate
Shane Ryan
sryan@bcaldiagnostics.com
+61 (0) 437 192 869

Investor Relations
Luke Maffei
luke.maffei@automicgroup.com.au
+61 (0) 403 193 579

Media
Rama Razy
rama.razy@automicgroup.com.au
+61 (0) 498 440 142

About BCAL

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST plus™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc. ("ClearNote Health"), a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect Multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, AUS and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.